Everolimus‐ and Zotarolimus‐Eluting Stents for Bare Metal Stent In‐Stent Restenosis Treatment: A Prospective Study

Abstract

In this prospective study, we showed that direct nDES implantation is highly effective for ISR and seems to be a promising management for the treatment of ISR.

Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug-Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment of Native Vessel In-Stent Restenosis in Real-World Clinical Practice

“…The safety endpoint comprised a composite of allcause death and non-fatal myocardial infarction. Major adverse cardiac events, a composite of cardiac death, non-fatal myocardial infarction and target vessel revascularisation was considered for the purposes of increased comparability with previous studies [2,15,20]. To prevent double counting of individual end-points within the composite endpoints a hierarchical count of endpoints was utilised such that death took priority over MI over TVR over angina.…”

“…More limited data exist regarding the efficacy of secondgeneration DES in the treatment of either BMS or DES ISR, despite the widespread use of both stent types in ISR treatment. Current evidence has been limited to a prospective study directly comparing ZES and EES [15] with limited sample sizes and no comparison to first-generation DES. A larger non-randomised study compared EES to PES in BMS ISR only and found reduced adverse event rates at one year in the EES group, and no difference in rates at long-term follow-up [16].…”

Meta-analysis of Trials Comparing Drug-eluting Stents with Bare Metal Stents: Safety and Efficacy

“…On the basis of this finding, their implantation has become increasingly common over the recent years and a majority of > 2 million patients are taking at least one type of these novel stents [56]. Although new types of DESs have been developing [57], however, SESs and PESs have been implanted more than the others and most of the published RCTs have utilized the two thus far [1,2,4,6,7,[12][13][14][15][16][17][18][19][42][43][44][45][46][47][48][49][50][51][52][53][54]. Notwithstanding the agreement of several studies with dramatic restenosis benefits of SESs [1,43,45,46] and PESs 2-4,7,50,51,54] compared with BMSs, there are considerable discrepancies among RCTs, [1,2,4,6,7,[12][13][14][15][16][17][18][19][42]…”